Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2018
Reporting Period: Third Quarter 2018
Emerging Growth Company: Yes
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification that the Company issued a press release containing these results, which is attached as Exhibit 99.1. The specific financial data is not embedded within the body of this current report.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document references the issuance of a press release regarding Q3 2018 operational highlights but does not summarize the specific changes versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company announced financial results and operational highlights for the third quarter of 2018 via a press release.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information furnished in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, unless specifically incorporated by reference by the Company.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated November 15, 2018) for actual Q3 2018 financial figures.
- Verify the Company's status as an Emerging Growth Company and any associated accounting election implications.
- Confirm that the financial data in the press release is not automatically incorporated by reference into other SEC filings unless explicitly stated by the Company.